EX-99.B 4 y59755ex99-b.txt CERTAIN SUPPLEMENTAL INFORMATION Exhibit 99(b) MERCK & CO., INC. CONSOLIDATED FIRST QUARTER
1Q `02 1Q `01 % CHG. -------------------------------------------------------------------------------- TOTAL SALES $ 12,169.3 $11,345.1 7% ---------- --------- TOTAL COSTS, EXPENSES, & OTHER $ 9,847.8 $ 8,977.6 ---------- --------- Materials & Production 7,980.7 7,046.5 Marketing & Administrative 1,464.8 1,506.2 Research & Development 530.3 547.4 Equity Income From Affiliates (171.8) (178.6) Other (Income)/Expense, Net 43.8 56.1 PRE-TAX INCOME $ 2,321.5 $ 2,367.5 TAXES $ 696.5 $ 710.2 TAX RATE 30.0% 30.0% NET INCOME $ 1,625.0 $ 1,657.3 -2% EPS - ASSUMING DILUTION $0.71 $0.71 0% AVG. # SHARES - ASSUMING DILUTION 2,294.8 2,345.9
1Q `02 % CHG. VOL PX FX -------- ------ ---- ---- ---- TOTAL SALES $ 12,170 7% 3 5 -1 -------- ---- ---- ---- ---- Total Pharmaceutical Sales 4,865 -2% 3 -2 -3 -------- ---- ---- ---- ---- U.S. 3,140 0% 1 -1 0 Foreign 1,725 -5% 7 -3 -9 Other Medco Sales 7,305 14%
Exhibit 99(b) MERCK & CO., INC. ADDITIONAL DISCLOSURE CORE PHARMA BUSINESS FIRST QUARTER
1Q `02 1Q `01 % CHG. -------------------------------------------------------------------------------- TOTAL SALES $ 4,802.4 $ 4,895.9 -2% ---------- ---------- TOTAL COSTS, EXPENSES, & OTHER $ 2,589.3 $ 2,616.2 ---------- --------- Materials & Production 864.1 862.7 Marketing & Administrative 1,343.3 1,375.1 Research & Development 530.3 547.4 Equity Income From Affiliates (171.8) (178.6) Other (Income)/Expense, Net 23.4 9.6 PRE-TAX INCOME $ 2,213.1 $ 2,279.7 -3% TAXES $ 655.1 $ 663.4 TAX RATE 29.6% 29.1% NET INCOME $ 1,558.0 $ 1,616.3 -4% --------------------------------------------------------------------------------
The above table reflects financial results for Merck & Co., Inc. on a stand-alone basis, excluding the results of Merck-Medco operations. Included in the above amounts are the necessary adjustments relating to transactions between Merck and Merck-Medco to put Merck on a stand-alone basis. Accordingly, the stand-alone financial results of Merck (excluding Merck-Medco) and Merck-Medco, when combined, are not reflective of Merck's consolidated financial results. Exhibit 99(b) MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES FIRST QUARTER 2002 ================================================================================ OTHER (INCOME)/EXPENSE, NET
------------------------ 1Q `02 1Q `01 ---------------------------------------------------------------------- INTEREST INCOME $ (98.4) $ (136.1) INTEREST EXPENSE 95.3 110.7 EXCHANGE (GAINS)/LOSSES (2.7) (12.6) MINORITY INTERESTS 50.7 85.2 AMORTIZATION OF GOODWILL AND INTANGIBLES 51.4 80.6 Other, net (52.5) (71.7) ------------------------ TOTAL $ 43.8 $ 56.1 ----------------------------------------------------------------------
================================================================================ JOINT VENTURE SALES DETAIL All sales reported here are end-market JV sales, presented on a "NET" basis, rounded to the nearest $5 million.
------------------------- MERIAL 1Q `02 1Q `01 ---------------------------------------------------------------------- IVOMEC, HEARTGARD, other avermectins $ 100 $ 110 FRONTLINE 120 115 Biologicals 85 80 Other Animal Health 45 45 Poultry Genetics 50 50 ------------------------ TOTAL MERIAL SALES $ 400 $ 400 ----------------------------------------------------------------------
------------------------- AVENTIS PASTEUR-MSD 1Q `02 1Q `01 ---------------------------------------------------------------------- HEPATITIS VACCINES $ 15 $ 25 VIRAL VACCINES 5 15 Other Vaccines 70 65 ------------------------ TOTAL AP-MSD SALES $ 90 $ 105 ----------------------------------------------------------------------
================================================================================ Exhibit 99(b) MERCK & CO., INC. PRODUCT SALES DETAIL
==================================================================================== 1Q `02 vs. 1Q `01 ==================================================================================== TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ ----------------------------------------------------------------------------------------------------------------------- VIOXX 34% $ 650 37% $ 480 26% $170 ARCOXIA N/M 5 N/M -- N/M 5 VASOTEC / VASERETIC -27% 190 -57% 15 -22% 175 PRINIVIL / PRINZIDE -10% 330 -9% 310 -20% 20 COZAAR / HYZAAR 19% 460 61% 225 -4% 235 MEVACOR -55% 65 -60% 50 -25% 15 ZOCOR 6% 1,605 8% 1,130 2% 475 AGGRASTAT -17% 25 -33% 10 0% 15 SINGULAIR 57% 470 65% 380 29% 90 MAXALT 45% 80 33% 60 N/M 20 PROPECIA 0% 50 -33% 20 50% 30 PROSCAR 0% 125 0% 60 0% 65 PRIMAXIN -14% 125 -25% 30 -10% 95 INVANZ N/M 5 N/M 5 N/M -- CANCIDAS N/M 15 N/M 10 N/M 5 PEPCID -92% 15 -94% 10 -67% 5 FOSAMAX 60% 560 76% 430 24% 130 CRIXIVAN/STOCRIN -44% 70 -38% 25 -47% 45 TIMOPTIC/TIMOPTIC XE -33% 40 -33% 10 -33% 30 TRUSOPT/COSOPT -5% 90 -27% 40 25% 50 HEPATITIS VACCINES -39% 55 -38% 50 -50% 5 VIRAL VACCINES -28% 90 -23% 85 -67% 5 OTHER VACCINES -60% 10 N/M 5 N/M 5 -----------------------------------------------------------------------------------------------------------------------
NOTE: Product sales rounded to the nearest $5 million. N / M - Not Meaningful